Know Cancer

forgot password

The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family: A Pilot Study

Open (Enrolling)
Financial Impact of Stem Cell Transplantion

Thank you

Trial Information

The Financial Impact of Allogeneic Stem Cell Transplantation on Patient and Family: A Pilot Study

Allogeneic hematopoietic stem cell transplantation (HSCT) is the indicated treatment for
many life-threatening illnesses affecting both adults and children. Transplant recovery and
late effects require long-term medical care. At the same time that the family faces a
medical crisis, a resulting financial crisis may also be pending, but is often pushed to the
background due to the necessity of first preserving life. A large proportion of patients
undergoing HSCT incur significant financial burden from out-of-pocket costs and a decrease
in household income. Predetermined variables, both medical and demographic, gathered at the
pre-transplant clinical consultation have the potential to predict the patients at greatest
financial risk. This study will describe both the out-of-pocket costs and the income changes
that may result from HSCT to help patients and their caregivers have a clearer picture of
these costs and develop a financial plan. Health care providers can utilize this
information to better inform patients and connect them to resources.

Inclusion Criteria:

1. Adult recipients and parents/guardians of pediatric (age 0-17 years) recipients of
allogeneic HSCT

2. Recipient has a primary caregiver, who is a member of the recipient's household

3. Allogeneic HSCT using any donor cell source (related, unrelated, or cord blood)

4. Any age at HSCT

5. Diagnosis of primary disease for which HSCT is being performed must have been made
within two years prior to transplantation

6. Adult recipients, parents/guardians of pediatric recipients, and primary caregivers
should be able to read, write, and understand the English language

7. Signed informed consent from adult patient, caregiver and/or parent/guardian for
study participation

8. Signed consent to participate in the Center for International Blood and Marrow
Transplant Research (CIBMTR) research database.

Exclusion Criteria:

1. Recipients who have had a previous HSCT (autologous or allogeneic)

2. Households with more than one transplant recipient

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To study the feasibility of using a patient maintained diary to capture out-of-pocket costs over the first 3 months following allogeneic HSCT

Outcome Time Frame:

Pre-transplant and for 3 months post-transplant

Safety Issue:


Principal Investigator

Navneet Majhail, MD, MS

Investigator Role:

Study Chair

Investigator Affiliation:

University of Minnesota / CIBMTR


United States: Institutional Review Board

Study ID:




Start Date:

March 2009

Completion Date:

September 2012

Related Keywords:

  • Financial Impact of Stem Cell Transplantion
  • Stem cell transplantation
  • Financial impact



Roswell Park Cancer InstituteBuffalo, New York  14263
Medical College of WisconsinMilwaukee, Wisconsin  53226
University of MinnesotaMinneapolis, Minnesota  55455